Ex Vivo Drug Response Profiling and Outcome Prediction in Lung Adenocarcinoma

This observational study evaluates if ex-vivo lung cancer drug sensitivity testing results correlate with the driver mutations found by genetic sequencing and if it can predict treatment response.

Inclusion Criteria: * Presence of pleural effusion in patient with a diagnosis of a lung cancer or suspected to be diagnosed with lung cancer according to their CT imaging, who are in need for pleural effusion drainage due to shortness of breath, and are willing to donate effusion for ex-vivo drug sensitivity testing. * Patient's written informed consent present. * Ability to understand the nature of the trial and the trial related procedures and to comply with them. Exclusion Criteria: * negative cytology for malignancy in the last 6 months